3,804 results match your criteria: "Oncology Centre.[Affiliation]"
Eur J Surg Oncol
September 2024
SIREDO Oncology Centre (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris-Saclay University (PSL), Paris, France.
Background And Aims: Alveolar soft part sarcoma (ASPS) is an ultra-rare chemo-resistant sarcoma in children, occurring preferentially in young adults. We aimed to describe and compare its clinical presentation and behaviour in children and young adults to determine whether the same therapeutic strategy should be addressed for both populations.
Methods: National retrospective multicentre study of children (0-18 years) vs.
Breast
August 2024
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Global Alliance. It provides the main recommendations on how to best manage patients with advanced breast cancer (inoperable locally advanced or metastatic), of all breast cancer subtypes, as well as palliative and supportive care. These guidelines are based on available evidence or on expert opinion when a higher level of evidence is lacking.
View Article and Find Full Text PDFA universal newborn screening program for sickle cell disease (uNS-SCD) was implemented in the province of Québec (Qc) in November 2013, close in time to the recommendation of early initiation of hydroxyurea (HU) therapy for children. This retrospective cohort study evaluated the impact of such a program on children first seen between January 2000 and December 2019. Cohorts pre-SCD-uNS in Qc (pre-QcNS) ( = 253) and post-QcNS ( = 157) for patients seen prior to or after Nov 2013 were compared.
View Article and Find Full Text PDFCancers (Basel)
May 2024
Oncology and Chemotherapy Clinic, Maria Sklodowska-Curie Memorial Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Background: This was an observational study prospectively evaluating the effectiveness and safety of aflibercept/FOLFIRI administered in second-line mCRC per the reimbursement criteria in Poland.
Methods: Consecutive mCRC patients who progressed with first-line oxaliplatin-based chemotherapy received aflibercept (4 mg/kg IV) followed by FOLFIRI every 2 weeks until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS); overall survival (OS) and safety were the secondary endpoints.
Animals (Basel)
June 2024
Laboratory of Aquatic Biomedicine, College of Veterinary Medicine, Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.
Despite the precarious state of marine turtles as a highly endangered species, our understanding of their diseases remains limited. This case report presents a detailed pathological investigation of spirorchiidiasis, a blood fluke infection that poses a substantial threat to marine turtles. This retrospective study examined three cases of spirorchiid-infected sea turtles, specifically, green sea turtles stranded on Jeju Island, South Korea.
View Article and Find Full Text PDFFuture Oncol
October 2024
Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Immune checkpoint inhibitors are licensed for use in patients with unresectable, recurrent or metastatic head and neck squamous cell carcinoma. Multiple published and ongoing trials are assessing efficacy in the curative management of patients in the concomitant, neoadjuvant and/or adjuvant settings, as well as part of multimodality treatment in patients with metastatic disease. This review evaluates the evidence for use of immune checkpoint inhibitors in all stages of head and neck squamous cell carcinoma and considers future approaches.
View Article and Find Full Text PDFCancer Control
June 2024
Department of Physiological Sciences, Faculty of Science, University of Stellenbosch, Stellenbosch, South Africa.
Cervical cancer is the fourth most common cancer in women. Advanced stage and metastatic disease are often associated with poor clinical outcomes. This substantiates the absolute necessity for high-throughput diagnostic and treatment platforms that are patient and tumour specific.
View Article and Find Full Text PDFOphthalmology
September 2024
NHS Digital Services, Liverpool University Hospitals NHS Foundation Trust, Kilby House, Liverpool Innovation Park, Liverpool, UK.
Mol Clin Oncol
July 2024
Department of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Kingdom of Saudi Arabia.
Low-grade serous ovarian cancer (LGSOC) is a very rare histological subtype of serous ovarian cancer, representing ~2% of all epithelial ovarian cancer cases. LGSOC has a better prognosis but a lower response rate to chemotherapy in comparison to high-grade serous ovarian carcinoma (HGSOC). The present study is a retrospective review of the medical records of all patients with histologically proven LGSOC diagnosed and treated in a single institute between January 2003 and December 2019.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
November 2024
Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom.
Purpose: Primary soft tissue sarcoma (STS) is rare, with many tumors occurring in extremities. Local management is limb-sparing surgery and preoperative/postoperative radiation therapy (RT) for patients at high risk of local recurrence. We prospectively investigated late normal tissue toxicity and limb function observed after intensity modulated RT (IMRT) in extremity STS.
View Article and Find Full Text PDFFront Oncol
May 2024
Urology Center, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong SAR, China.
Background: Muscle-invasive bladder cancer (MIBC) with nodal involvement is associated with poor prognosis and high mortality. Treatment of node-positive MIBC is complex due to disease heterogeneity and a lack of evidence-based treatment options, especially alternatives to radical cystectomy. We describe a bladder-sparing management approach involving systemic therapy followed by maintenance therapy, illustrated with two cases of node-positive MIBC.
View Article and Find Full Text PDFRadiother Oncol
August 2024
Proton Therapy Center, 'S. Chiara' Hospital, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Lancet
June 2024
Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.
Clin Oncol (R Coll Radiol)
September 2024
Northern Centre for Cancer Care, Freeman Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, NE77DN, UK.
Aims: WHO Grade 3 (G3) meningiomas are rare tumours with limited data to guide management. This retrospective study documents UK management approaches across 14 centres over 11 years.
Materials And Methods: Patients with WHO G3 meningioma between 01/01/2008 and 31/12/2018 were identified.
Oncologist
September 2024
Surgical Oncology Department, Mansoura University Oncology Centre, Mansoura, Egypt.
This commentary focuses on 5 questions that need to be answered when considering sentinel lymph node biopsy in breast cancer, aiming to highlight these issues and provide researchers with ideas to resolve.
View Article and Find Full Text PDFFront Oncol
May 2024
Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Introduction: Mixed-phenotype acute leukemia (MPAL) is a rare disease with poor prognosis. So far, no standard approach has been established as the "know-how" of MPAL is based only on retrospective analyses performed on small groups of patients.
Materials And Methods: In this study, a retrospective analysis of the outcomes of adult MPAL patients included in the PALG registry between 2005 and 2024 who received the CLAG-M hybrid protocol as induction or salvage therapy was performed.
J Pediatr Hematol Oncol
August 2024
Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain.
Human herpesvirus 6 (HHV-6) is a widely spread DNA virus that is ubiquitous and persistent with primary infection occurring in early childhood, with reactivation of the infection a common phenomenon in severely immunocompromised hosts, including hematopoietic stem cell transplant (HSCT) patients, influencing morbidity and mortality. A wide spectrum of clinical presentations is reported in the literature with HHV-6 reactivation including post-transplant limbic encephalitis (PALE). We report the unusual case of a 6-year-old female 107 days postallogenic HSCT due to transfusion dependent beta thalassemia major who developed acute cerebellitis with secondary supratentorial hydrocephalus that required invasive surgical intervention.
View Article and Find Full Text PDFSaudi Med J
June 2024
From the College of Medicine (Abu Khizanah, Tashkandi); from the Facility of Pharmacy (Al-ahmdi, Almehmadi), Umm Al-Qura University, from the Department of Medical Oncology (Tashkandi, Elnaghi), Oncology Centre; from the Department of Pharmacy (Jaffal), King Abdullah Medical City, Makkah, from the Department of Medicine (Alsaedi), Ibn Sina National College for Medical Studies, Jeddah, Kingdom of Saudi Arabia, and from the Department of Medical Oncology (Elnaghi), Oncology Center, Mansoura University, Mansoura, Egypt.
Objectives: To describe the current real-world treatment landscape, sequence of therapies, and outcomes in patients with prostate cancer (PC).
Methods: A retrospective cohort study for PC patients diagnosed at King Abdullah Medical City Cancer Center in Makkah, Saudi Arabia, between January 2011 and December 2021. Data extracted from electronic medical records.
Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with and without chemotherapy was compared with chemotherapy alone in patients with metastatic urothelial cancer. The study did not meet prespecified efficacy thresholds for statistical significance.
View Article and Find Full Text PDFPediatr Blood Cancer
August 2024
SIREDO Oncology Centre (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
BMC Vet Res
May 2024
Laboratory of Aquatic Biomedicine, College of Veterinary Medicine, Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea.
Contemp Oncol (Pozn)
May 2024
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Materials (Basel)
May 2024
Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Kasztanowa 3, 41-205 Sosnowiec, Poland.
Aim: the aim of the work was to present the changes occurring on the model and historical cotton surface of cotton resulting from disinfection with 90% ethanol mist.
Materials And Methods: Samples of historical materials consisted of fabric elements from suitcases stored in A-BSM. A mist of 90% ethanol was applied for 15 s at a distance of 16 cm from the surface.
BMC Cancer
May 2024
Baylor University Medical Center, Texas Oncology, US Oncology, 3410 Worth Street, Suite 400, Dallas, TX, 75246, USA.
Background: HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. Bi-directional crosstalk leads to cooperation of the HER2 and ER pathways that may drive treatment resistance; thus, simultaneous co-targeting may optimize treatment impact and survival outcomes in patients with HER2+, ER+ BC. First-line (1L) treatment for patients with HER2+ metastatic BC (mBC) is pertuzumab, trastuzumab, and taxane chemotherapy.
View Article and Find Full Text PDFJ Fungi (Basel)
May 2024
National Aspergillosis Centre, Department of Infectious Diseases, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK.
Chronic pulmonary aspergillosis (CPA) is a rare but significant complication of lung cancer surgery. Its effect on survival remains unclear. Our aim was to describe the outcomes of the patients who developed CPA following the surgery for non-small cell lung cancer (NSCLC), identify the risk factors associated with its development following lung resection, and evaluate its impact on survival.
View Article and Find Full Text PDF